Gert-Jan Braunstahl
Franciscus Gasthuis & Vlietland
asthma
exacerbations
abpa
allergic bronchopulmonary aspergillosis
dupilumab
inflammation
allergy
respiratory tract infections
bacterial lysates
adult-onset asthma
metabolic syndrome
lipid mediators
immune modulation
type 2 inflammation
covid-19
5
presentations
SHORT BIO
Gert-Jan Braunstahl is a pulmonologist working in a tertiary severe asthma center in Rotterdam with a wide-spread network in the South-West part of the Netherlands. He did part of his scientific and professional training abroad in Canada (McMaster University, Hamilton) and South-Africa (Grote Schuur Hospital, Cape Town). After his training at the ErasmusMC in Rotterdam and completing his thesis on the nasobronchial interaction in allergic rhinitis and asthma, he started working as an asthma specialist in 2006 in the Franciscus Gasthuis & Vlietland hospital. His initial scientific work has significantly contributed to the “united airways” concept. After this the focus has shifted towards clinical application of fractionated nitric oxide (FeNO) in respiratory allergy. Nowadays, he is involved in several lines of research, such as morbid obesity and asthma, aging of the asthmatic lung, bacterial lysates and prevention of asthma exacerbations, and several clinical studies investigating biologicals in asthma. He holds a position as an associate professor at Erasmus MC and is head of the section Asthma and Allergy of the NVALT.
Presentations
Roadmap to improve regional care for severe asthma patients in the Netherlands
Gert-Jan Braunstahl and 8 other authors
Asthma exacerbation prevalence during the COVID-19 lockdown in a moderate-severe asthma cohort
Geertje de Boer and 3 other authors
Prevention of exacerbations in moderate-severe asthma by bacterial lysate add-on therapy: a randomized controlled trial
Geertje de Boer and 8 other authors
Adult but not childhood onset asthma is associated with the metabolic syndrome, independent from body mass
Geertje de Boer and 8 other authors
Case series: asthmatic patients with allergic bronchopulmonary aspergillosis (ABPA) treated with dupilumab
Tjeerd van der Veer and 3 other authors